Risk From Pharma Reps Using Unapproved Content and Messaging in the Field Persists, but a Focus on Training Could Be the Answer TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ACTO, the #1 Learning Platform in Life Sciences, today announced the results of a new study that explored the prevalence and impact of the use of...

ACTO Recognized as “Life Sciences Commercial Analytics and AI Trailblazer” by Everest Group TORONTO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- ACTO, the #1 learning platform in Life Sciences, has been recognized as a Trailblazer in Life Sciences Commercial Analytics and Artificial Intelligence...

ACTO Secures $18M Financing to Accelerate Growth and Strengthen Position as #1 Learning Platform in Life Sciences TORONTO, July 07, 2022 (GLOBE NEWSWIRE) -- ACTO, the omnichannel learning and enablement platform for life sciences, today announced the closing of a US$18 million equity financing. The investment...

ACTO launches LAICA™, the first AI-powered conversational assistant for Life Sciences learning TORONTO, June 15, 2022 (GLOBE NEWSWIRE) -- ACTO, the only complete commercial learning platform for the Life Science industry, announced the launch of "LAICA™", an artificial intelligence...

ACTO Bolsters Executive Management Team to Meet Significant US Commercial Growth TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- ACTO, the only complete commercial learning platform for the life science industry, is strengthening its executive management team with two key additions to...